The fourth generation ceramic, in which zirconia is incorporated into the alumina matrix, was developed to reduce the risk of ceramic fractures. The purpose of this study was to evaluate the survivorship, clinical and radiographic results, and bearing-related failures associated with total hip arthroplasty using zirconia-toughened alumina ceramic-on-ceramic bearings over a minimum follow-up of 5 years. We retrospectively analysed 135 patients (151 hips) who underwent cementless total hip arthroplasty using zirconia-toughened alumina ceramic-on-ceramic bearings. There were 58 men and 77 women with mean age of 55.9 years (range, 20 to 82 years) at index surgery. Acetabular and femoral components were cementless in all hips. A 36 mm head was used in 81 of 151 hips and a 32 mm head was used in 70 hips with smaller acetabular shells. The mean duration of follow-up was 6.1 years (range, 5 to 6.8 years).Purpose
Materials and methods
The use of tranexamic acid (TXA) in primary total hip arthroplasty (THA) is supported by many studies that confirm its efficacy for decreasing blood loss, but the comparison between topical intra-articular (IA) and intra-venous (IV) is unclear, especially combined with chemical prophylaxis. The purpose of this study is to verify non-inferior efficacy of topical IA TXA compared with IV TXA in primary THA. A single center, randomized, controlled clinical trial was performed to compare topical IA TXA (2 g of TXA in 100 cc of normal saline) with two IV doses of TXA (1 g dose before surgery and another 1 g dose 3 hours later) on blood loss. The primary outcome was total blood loss as calculated from the difference between the preoperative hemoglobin (Hb) and the lowest postoperative Hb. The secondary outcome included drained blood loss, transfusion volume, and thromboembolic events. The sample size of 112 patients was calculated to give a statistical power of 99% for demonstrating inferiority. Fifty-six patients each was assigned to receive topical IA TXA (IA group) and IV TXA (IV group). There were no significant differences in demographics and preoperative laboratory values between the two groups. Non-inferiority was estimated by comparing the confidence interval with a delta of 10%. All subjects took oral direct factor Xa inhibitor to prevent venous thromboembolism included during 2 weeks after surgery.Introduction
Methods & Methods
